Medpace Holdings, Inc. $MEDP Shares Purchased by The Manufacturers Life Insurance Company

Key Points

• The Manufacturers Life Insurance Company increased its Medpace stake by 38.9% in the second quarter, bringing its holdings to 20,043 shares valued at approximately $10.6 million. Institutional investors collectively own 77.98% of the company.
• Medpace insiders have been selling shares, including CEO August Troendle’s $16.8 million sale and Director Brian Carley’s $3.0 million sale. Insiders sold 134,471 shares worth roughly $82.2 million over the past three months.
• Medpace beat quarterly earnings and revenue expectations, reporting $4.25 EPS and $707.33 million in revenue, up 17.2% year over year. Despite strong results, analysts maintain a consensus “Hold” rating with an average price target of $595.20.

The Manufacturers Life Insurance Company raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 38.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,043 shares of the company's stock after purchasing an additional 5,610 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.07% of Medpace worth $10,615,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BOKF NA grew its stake in shares of Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company's stock valued at $1,307,000 after buying an additional 20 shares in the last quarter. Valeo Financial Advisors LLC boosted its holdings in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company's stock worth $249,000 after acquiring an additional 21 shares during the period. UMB Bank n.a. grew its position in Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company's stock valued at $253,000 after acquiring an additional 24 shares in the last quarter. Schulhoff & Co. Inc. grew its position in Medpace by 1.1% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock valued at $1,237,000 after acquiring an additional 25 shares in the last quarter. Finally, Balefire LLC raised its stake in shares of Medpace by 6.1% during the first quarter. Balefire LLC now owns 451 shares of the company's stock valued at $217,000 after purchasing an additional 26 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Activity

In other news, Director Brian Carley sold 5,000 shares of the business's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the transaction, the director owned 27,825 shares of the company's stock, valued at approximately $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO August Troendle sold 27,174 shares of the company's stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the transaction, the chief executive officer owned 561,195 shares of the company's stock, valued at $347,261,854.05. This represents a 4.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 134,471 shares of company stock worth $82,151,311. 20.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on MEDP. Robert W. Baird raised their price objective on Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a research note on Friday, July 24th. Jefferies Financial Group downgraded shares of Medpace from a "buy" rating to a "hold" rating and boosted their target price for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. TD Cowen upped their price objective on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Truist Financial increased their target price on Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $595.20.

Medpace Stock Performance

NASDAQ MEDP opened at $587.52 on Friday. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The company has a 50-day simple moving average of $579.00 and a 200-day simple moving average of $504.67. The firm has a market capitalization of $16.40 billion, a PE ratio of 34.44, a price-to-earnings-growth ratio of 2.62 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business's quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.